These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Comprehensive Predictions of Cytochrome P450 (P450)-Mediated In Vivo Cannabinoid-Drug Interactions Based on Reversible and Time-Dependent P450 Inhibition in Human Liver Microsomes. Bansal S, Paine MF, Unadkat JD. Drug Metab Dispos; 2022 Apr; 50(4):351-360. PubMed ID: 35115300 [Abstract] [Full Text] [Related]
3. Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions. Nasrin S, Watson CJW, Perez-Paramo YX, Lazarus P. Drug Metab Dispos; 2021 Dec; 49(12):1070-1080. PubMed ID: 34493602 [Abstract] [Full Text] [Related]
4. Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants. Bansal S, Zamarripa CA, Spindle TR, Weerts EM, Thummel KE, Vandrey R, Paine MF, Unadkat JD. Clin Pharmacol Ther; 2023 Sep; 114(3):693-703. PubMed ID: 37313955 [Abstract] [Full Text] [Related]
6. The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications. Qian Y, Gurley BJ, Markowitz JS. J Clin Psychopharmacol; 2019 Sep; 39(5):462-471. PubMed ID: 31433338 [Abstract] [Full Text] [Related]
7. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Stout SM, Cimino NM. Drug Metab Rev; 2014 Feb; 46(1):86-95. PubMed ID: 24160757 [Abstract] [Full Text] [Related]
8. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Yamaori S, Ebisawa J, Okushima Y, Yamamoto I, Watanabe K. Life Sci; 2011 Apr 11; 88(15-16):730-6. PubMed ID: 21356216 [Abstract] [Full Text] [Related]
13. Hepatic Enzymes Relevant to the Disposition of (-)-∆9-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, 11-OH-THC. Patilea-Vrana GI, Anoshchenko O, Unadkat JD. Drug Metab Dispos; 2019 Mar 11; 47(3):249-256. PubMed ID: 30567877 [Abstract] [Full Text] [Related]
17. Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: Pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration. Cherniakov I, Izgelov D, Barasch D, Davidson E, Domb AJ, Hoffman A. J Control Release; 2017 Nov 28; 266():1-7. PubMed ID: 28890215 [Abstract] [Full Text] [Related]
18. Drug-drug interactions as a result of co-administering Δ9-THC and CBD with other psychotropic agents. Rong C, Carmona NE, Lee YL, Ragguett RM, Pan Z, Rosenblat JD, Subramaniapillai M, Shekotikhina M, Almatham F, Alageel A, Mansur R, Ho RC, McIntyre RS. Expert Opin Drug Saf; 2018 Jan 28; 17(1):51-54. PubMed ID: 29082802 [Abstract] [Full Text] [Related]
19. Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC. Hložek T, Uttl L, Kadeřábek L, Balíková M, Lhotková E, Horsley RR, Nováková P, Šíchová K, Štefková K, Tylš F, Kuchař M, Páleníček T. Eur Neuropsychopharmacol; 2017 Dec 28; 27(12):1223-1237. PubMed ID: 29129557 [Abstract] [Full Text] [Related]